Cerus (CERS -0.2%) commences patient enrollment in two European Phase 3 clinical trials for its...

|About: Cerus Corporation (CERS)|By:, SA News Editor

Cerus (CERS -0.2%) commences patient enrollment in two European Phase 3 clinical trials for its Intercept System for red blood cells. One trial is being conducted for patients with acute anemia, while the other is a separate trial for patients with chronic anemia. The company is conducting the trials to support its CE Mark registration.